Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): A localized drug delivery approach to treat peritoneal carcinomatosis of different origins

Abstract

Pressurized Intraperitoneal Aerosol Chemotherapy or PIPAC has recently gained focus of researchers worldwide in the field of oncology for treating the notorious cancer peritoneal carcinomatosis. The aim of this review was to present a scientific overview of PIPAC for treating peritoneal carcinomatosis of different origins. The methodology of the research was based on reviewing the available scientific literature from reliable online resources. High pressure and aerosol dosage form are utilized in PIPAC to deliver chemotherapy intraperitoneally. Oxaliplatin and a combination of cisplatin followed by doxorubicin are the most frequently administered drugs in PIPAC. PIPAC exerts a high local activity with lower systemic effects. PIPAC has shown substantial tumor regression and efficacy. Some major and frequent minor adverse effects have been identified. Larger clinical trials are needed to clearly define the indications of PIPAC, assess its long-term toxicity, and expand its clinical use in the treatment of peritoneal carcinomatosis.